Binding molecules that bind CD137 and PD-L1
AssigneeMerus N.V.
InventorsCecilia Anna Wilhelmina Geuijen, Mark Throsby, Cornelis Adriaan De Kruif, Rinse Klooster, Paulus Johannes Tacken, Ton Logtenberg
Life of this patent
Estimating the term…
Abstract
The invention provides means and methods of stimulating activity of a member of the TNF receptor superfamily on a cell. The invention also provides binding molecules such as antibodies that comprises at least two antigen binding sites, wherein a first antigen binding site can bind an extracellular part of CD137 and a second antigen binding site can bind an extracellular part of PD-L1.
Claims10
A bispecific antibody that comprises a first antigen binding site that can bind an extracellular part of CD137 and a second antigen binding site that can bind an extracellular part of PD-L1;
- wherein the first antigen binding site comprises a first heavy chain variable region comprising the complementarity determining regions CDR1 of SEQ ID NO:250, CDR2 of SEQ ID NO:251, and CDR3 of SEQ ID NO:252;
- wherein the second antigen binding site comprises a second heavy chain variable region comprising CDR1 of SEQ ID NO:253, CDR2 of SEQ ID NO:254, and CDR3 of SEQ ID NO:255;
- and
- wherein the first and second antigen binding site comprise a common light chain comprising CDR1 of SEQ ID NO:256, CDR2 of AAS, and CDR3 of SEQ ID NO:257.
Dependencies are inferred from the claim text.